July 26 (Reuters) - Intellipharmaceutics International Inc IPCI.TO
* Intellipharmaceutics provides update on FDA advisory committees meeting for Rexista (oxycodone hydrochloride extended release), an abuse-deterrent opioid analgesic for the treatment of moderate to severe pain
* Intellipharmaceutics - Committees expressed desire to review additional safety data for Rexista
* Intellipharmaceutics International Inc - Intends to conduct category 3 abuse potential studies for Rexista(tm)
* Can be no assurance that we will not be required to conduct further studies for Rexista
* Intellipharmaceutics International - FDA set a prescription drug user fee act goal date of Sept 25 for completion of its review of Rexista NDA candidate
* Intellipharmaceutics International Inc - FDA advisory committee voted 22 to 1 in finding co's nda for Rexista should not be approved at this time